INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 194 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2018. The put-call ratio across all filers is 1.35 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,444,266 | +71.8% | 77,900 | +2.5% | 0.00% | 0.0% |
| Q2 2023 | $840,560 | -17.6% | 76,000 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,020,680 | +2.8% | 76,000 | -5.4% | 0.00% | 0.0% |
| Q4 2022 | $993,311 | +28.0% | 80,300 | +44.4% | 0.00% | 0.0% |
| Q3 2022 | $776,000 | +1.0% | 55,600 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $768,000 | -20.5% | 55,600 | -6.4% | 0.00% | 0.0% |
| Q1 2022 | $966,000 | -4.2% | 59,400 | -4.0% | 0.00% | 0.0% |
| Q4 2021 | $1,008,000 | +9.7% | 61,900 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $919,000 | -25.6% | 61,900 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $1,236,000 | -10.3% | 61,900 | +3.7% | 0.00% | 0.0% |
| Q1 2021 | $1,378,000 | -6.6% | 59,700 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $1,475,000 | -40.4% | 59,700 | 0.0% | 0.00% | -50.0% |
| Q3 2020 | $2,475,000 | -12.0% | 59,700 | +1.7% | 0.00% | 0.0% |
| Q2 2020 | $2,812,000 | -12.1% | 58,700 | +15.6% | 0.00% | -33.3% |
| Q1 2020 | $3,198,000 | -48.5% | 50,800 | +1.4% | 0.00% | -50.0% |
| Q4 2019 | $6,208,000 | +93.3% | 50,100 | +3.5% | 0.01% | +100.0% |
| Q3 2019 | $3,212,000 | -8.5% | 48,400 | +9.8% | 0.00% | -25.0% |
| Q2 2019 | $3,509,000 | -17.2% | 44,100 | +16.4% | 0.00% | -20.0% |
| Q1 2019 | $4,239,000 | +14.9% | 37,900 | +3.6% | 0.01% | 0.0% |
| Q4 2018 | $3,689,000 | -19.1% | 36,600 | +1.4% | 0.01% | 0.0% |
| Q3 2018 | $4,562,000 | +54.0% | 36,100 | +2.3% | 0.01% | +66.7% |
| Q2 2018 | $2,962,000 | +57.9% | 35,300 | +15.7% | 0.00% | +50.0% |
| Q1 2018 | $1,876,000 | +10.0% | 30,500 | +4.5% | 0.00% | 0.0% |
| Q4 2017 | $1,706,000 | +0.6% | 29,200 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $1,695,000 | -52.1% | 29,200 | 0.0% | 0.00% | -50.0% |
| Q2 2017 | $3,535,000 | +9.7% | 29,200 | +2.5% | 0.00% | 0.0% |
| Q1 2017 | $3,223,000 | +6.3% | 28,500 | +2.2% | 0.00% | -20.0% |
| Q4 2016 | $3,031,000 | -34.0% | 27,900 | 0.0% | 0.01% | -28.6% |
| Q3 2016 | $4,592,000 | +14.9% | 27,900 | -0.4% | 0.01% | +16.7% |
| Q2 2016 | $3,995,000 | +15.1% | 28,000 | 0.0% | 0.01% | 0.0% |
| Q1 2016 | $3,471,000 | +5.1% | 28,000 | +26.7% | 0.01% | -25.0% |
| Q4 2015 | $3,301,000 | -10.0% | 22,100 | 0.0% | 0.01% | -11.1% |
| Q3 2015 | $3,666,000 | -20.5% | 22,100 | +15.7% | 0.01% | -25.0% |
| Q2 2015 | $4,610,000 | -9.2% | 19,100 | +6.1% | 0.01% | -14.3% |
| Q1 2015 | $5,076,000 | +112.7% | 18,000 | +17.6% | 0.01% | +55.6% |
| Q4 2014 | $2,387,000 | -32.3% | 15,300 | +2.7% | 0.01% | -35.7% |
| Q3 2014 | $3,527,000 | +1.4% | 14,900 | +1.4% | 0.01% | +7.7% |
| Q2 2014 | $3,478,000 | – | 14,700 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |